ClinicalTrials.gg
CompletedNCT04551300Updated Oct 18, 2022

A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients

A Phase 2 interventional study of VS-505 and Sevelamer Carbonate in Hyperphosphatemia, sponsored by Shanghai Alebund Pharmaceuticals Limited. Completed at 23 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-18.

Sponsored by Shanghai Alebund Pharmaceuticals Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Hyperphosphatemia with a site in China — 6 open to participants now, 6 under way, 1 of them phase 3. Hyperphosphatemia · China.

Enrollment
8th of 15
158 · median 158
Started
2020
with 2 others
Phase 2
4 of 18
2 open now
Registered
10th of 18
by date

Among the 18 studies in Hyperphosphatemia with a site in China, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2020, is one of 4 in phase 2, and was the 10th registered.

Hyperphosphatemia

173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.

Browse Hyperphosphatemia studies →

Open to participants now

6 of the 18 studies in Hyperphosphatemia with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hyperphosphatemia with a site in China, or all of them as a file.
02

Study summary

A multi-center, open-label, parallel-design, active-controlled phase 2 study to evaluate the tolerability, safety and efficacy of various dosages of VS-505 compared with Sevelamer Carbonate when given orally with meal for 6 weeks to treat hyperphosphatemia in chronic kidney disease subjects receiving maintenance hemodialysis.

Read the detailed description

The main body of this study has 5 intervention arms, 4 VS-505 treatment arms of various dosage plus 1 active control arm of Sevelamer Carbonate, each consists 25 subjects. Prior to this main part, a dose escalating cohort of 25 subjects is added to evaluate the tolerability of VS-505 in Chinese patient population.

03

Conditions studied

  • Hyperphosphatemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with end stage renal disease who are receiving a stable hemodialysis regimen (3 times per week) with sufficient dialysis adequacy;
  • Serum phosphorus level range from >1.94 mmol/L (6.0 mg/dL) to ≤3.23 mmol/L (10.0 mg/dL) at the end of washout phase.

Exclusion criteria

Exclusion Criteria:

  • Kidney transplant patient or scheduled kidney transplant, or change to peritoneal dialysis, home hemodialysis or plan to relocate to another dialysis center during the study period;
  • Serum phosphorus level is \<1.29 mmol/L(4.0 mg/dL) or >2.42 mmol/L(7.5 mg/dL) at screening, or documented to be >3.23 mmol/L(10 mg/dL) within the latest three month prior to screening (screening included);
  • Serum calcium level is \<8 mg/dL or >11 mg/dL at the screening;
  • Serum immunoreactive parathyroid hormone (iPTH)>1000 pg/mL at the screening;
  • History of hemochromatosis or serum ferritin value ≥1000 μg/L at screening;
  • Current gastrointestinal (GI) disorder, or history of intestine obstruction, gastrectomy or duodenectomy, or GI tract surgery within 12 weeks prior to screening;
  • Poorly controlled hypertension, cardiovascular disorders, and history of cerebrovascular disease or cardiovascular disease event within 24 weeks (6 months) prior to screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    VS-505 500mg

    VS-505 500mg (two 250 mg capsules) oral administration three times a day with meal, daily total dosage 1500mg.

    Drug: VS-505

  • Experimental
    VS-505 750mg

    VS-505 750mg (one 750 mg capsule) oral administration three times a day with meal, daily total dosage 2250mg.

    Drug: VS-505

  • Experimental
    VS-505 1500mg

    VS-505 1500mg (two 750 mg capsules) oral administration three times a day with meal, daily total dosage 4500mg.

    Drug: VS-505

  • Experimental
    VS-505 2250mg

    VS-505 2250mg (three 750 mg capsules) oral administration three times a day with meal, daily total dosage 6750mg.

    Drug: VS-505

  • Active comparator
    Sevelamer Carbonate 1600mg

    Sevelamer Carbonate 1600mg (two 800mg pills) oral administration three times a day with meal, daily total dosage 4800mg.

    Drug: Sevelamer Carbonate

Interventions

  • DrugVS-505

    4 dosages of experimental drug

  • Active Comparator

    Also known as: Renvela

06

What researchers measure

Primary outcomes

  1. Serum phosphorus change from baseline to end of treatment

    Time frame: 6 weeks

Secondary outcomes

  1. Time to serum phosphorus response,defined as serum phosphorus level decrease by 0.32 mmol/L(1 mg/dL)and serum phosphorus level below 1.78 mmol/L(5.5 mg/dL)

    Time frame: 6 weeks

  2. The achievement rate of subjects with serum phosphorus in the target range 1.13-1.78 mmol/L(3.5-5.5 mg/dL)by the end of treatment

    Time frame: 6 weeks

  3. Serum calcium change from baseline to end of treatment

    Time frame: 6 weeks

  4. Serum Ca×P change from baseline to end of treatment

    Time frame: 6 weeks

  5. Serum iPTH change from baseline to end of treatment

    Time frame: 6 weeks

Other outcomes

  1. Serum ferritin change from baseline to end of treatment

    Time frame: 6 weeks

  2. Number of serious adverse events (SAEs)

    Time frame: 6 weeks

07

Study locations

23 sites
  • Peking University People's Hospital
    Beijing, Beijing, China
  • Peking University Third Hospital
    Beijing, Beijing, China
  • Zhongshan Hospital Xiamen University
    Xiamen, Fujian, China
  • Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi, China
  • The Third Hospital of Hebei Medical University
    Shijia Zhuang, Hebei, China
  • The Second Affiliated Hospital of Xingtai Medical College
    Xingtai, Hebei, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei, China
  • The Second People's Hospital of Changzhou
    Changzhou, Jiangsu, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu, China
  • Affiliated Hospital of Nantong University
    Nantong, Jiangsu, China
  • Wuxi People's Hospital
    Wuxi, Jiangsu, China
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu, China
  • Jilin Province People's Hospital
    Changchun, Jilin, China
  • The Second Hospital of Jilin University
    Changchun, Jilin, China
  • Dalina Municipal Central Hospital
    Dalian, Liaoning, China
  • The First Hospital of Dalian Medical University
    Dalian, Liaoning, China
  • The Second Hospital of Dalian Medical University
    Dalian, Liaoning, China
  • Shanghai General Hospital
    Shanghai, Shanghai, China
  • Shanghai Tenth People's Hospital
    Shanghai, Shanghai, China
  • Xinhua Hospital Affiliated to Shanghai Jiao Tong Universiity School of Medcine
    Shanghai, Shanghai, China
  • The Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • Tianjin People's Hospital
    Tianjin, Tianjin, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jun 2022, 20 months.

Of 13 phase 2 interventional studies under Hyperphosphatemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 10. This study's 20 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2020
First posted
Sep 16, 2020
StartActual
Oct 13, 2020
Primary completionActual
Jun 30, 2022
CompletionActual
Oct 15, 2022
Last update
Oct 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04551300
Lead sponsor
Shanghai Alebund Pharmaceuticals Limited
Responsible party
Sponsor
First posted
Sep 16, 2020
Start date
Oct 13, 2020
Primary completion
Jun 30, 2022
Completion
Oct 15, 2022
Last update
Oct 18, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion